(Q37072216)

18 August 2017

1 reference

title

PPARs and the kidney in metabolic syndrome (English)

1 reference

18 August 2017

1 reference

Xiongzhong Ruan

1

1 reference

18 August 2017

Feng Zheng

series ordinal

2

1 reference

18 August 2017

Youfei Guan

series ordinal

3

1 reference

18 August 2017

publication date

30 January 2008

1 reference

American Journal of Physiology - Renal Physiology

18 August 2017

published in

1 reference

18 August 2017

volume

294

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

F1032-47

1 reference

Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Fibrates: what have we learned in the past 40 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

IGF-1 induces rat glomerular mesangial cells to accumulate triglyceride

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Vascular effects of TZDs: new implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Differential activation of adipogenesis by multiple PPAR isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Troglitazone action is independent of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor-alpha deficiency protects aged mice from insulin resistance induced by high-fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

mRNA expression for insulin-like growth factor 1, receptors of growth hormone and IGF-1 and transforming growth factor-beta in the kidney and liver of Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARdelta is a very low-density lipoprotein sensor in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Emerging roles of PPARs in inflammation and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptors in inflammation control

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Phosphorylation of PPARs: from molecular characterization to physiological relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Regulation of adipocytokines and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Effect of lipid reduction on the progression of renal disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Regulatory functions of PPARbeta in metabolism: implications for the treatment of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function: lessons from human genetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Muscle-specific Pparg deletion causes insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor gamma agonists in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPAR delta agonists and metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Metabolic Syndrome Epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

An overview on biological mechanisms of PPARs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Transcriptional repression of atherogenic inflammation: modulation by PPARdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARdelta regulates glucose metabolism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Activation of PPARdelta alters lipid metabolism in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Adiponectin and Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

New drug targets for type 2 diabetes and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The metabolic syndrome and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Energy metabolism and cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Safety issues and prospects for future generations of PPAR modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

15-Deoxy-Delta12,14-prostaglandin J2 inhibits IL-1beta-induced cyclooxygenase-2 expression in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Diagnosis, prevention, and intervention for the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPAR gamma and human metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The next generation of PPAR drugs: do we have the tools to find them?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Resistin, obesity, and insulin resistance--the emerging role of the adipocyte as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Role of peroxisome proliferator-activated receptor-alpha in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome proliferator-activated receptor-gamma is involved in the control of renin gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

c-Fos-driven transcriptional activation of transforming growth factor β-1: inhibition of high glucose-induced promoter activity by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Anti-inflammatory effect of PPARgamma in cultured human mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

PPAR-gamma agonists and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Addressing the insulin resistance syndrome: a role for the thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00152.2007

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

21 January 2018

1 reference

COCI

https://opencitations.net/index/coci/api/v1/citations/10.1038/47254

10.1152/AJPRENAL.00152.2007

15 July 2023

Identifiers

DOI

1 reference

18 August 2017

1 reference